CLEC2D Protein Helps Triple-Negative Breast Cancer Evade Immune System

Scientists have identified a protein that helps one of the hardest breast cancers to treat hide from the immune system. The protein is called CLEC2D and it is linked to worse outcomes in triple-negative breast cancer. In lab tests, cancer cells with high levels of CLEC2D weakened the ability of T cells to attack tumours. The protein also acts as a checkpoint signal for natural killer cells by binding to a receptor called CD161. Blocking that signal with an antibody improved T cell attacks against tumours with high CLEC2D. The protein also helped cancer cells grow, survive, move, and spread on their own. It worked through a partner protein called integrin beta 4 and a signalling chain that drives aggressive behaviour. The study suggests CLEC2D and its pathway could become a new target for future treatments.

image
advertisement
"We will never ask you to login, or register through a third-party advertisement."